ProQR Therapeutics (PRQR) said Wednesday that it will receive an additional $8.1 million research grant from Rett Syndrome Research Trust to support its clinical trials of drug candidate AX-2402.
The grant brings the research trust's total funding in ProQR to $9.1 million, ProQR said.
Rett Syndrome is a rare neurodevelopmental disorder that causes a regression of a child's language and motor skills.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。